Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative

ESMO 2012

28 Sep - 2 Oct 2012

Published: 9 Oct 2012

Views: 7234

Rating:

Save

Dr Paolo Casali – Instituto Nazionale Tumori, Milan, Italy

Dr Paolo Casali talks to ecancer at the 2012 ESMO meeting in Vienna about personalised medical therapy of soft tissue sarcomas.

This approach involves using histology and tailoring therapy based on each tumours genomics.

These complicated procedures require a lot analysis with molecular biology had increases problems in developing clinical trials.

Dr Casali also talks about the announcement of the launch of Rare Cancers Europe at ESMO 2012. This multidisciplinary initiative looks at the issues of creating clinical studies for rare cancers in order to quicken the development of drugs for clincial use.

Filming supported by Amgen

Related Videos

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours

Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours ( Dr Maria Vieito - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Transforming cancer care in India: The Access Cancer Care Initiative

Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran

Transforming cancer care in India: The Access Cancer Care Initiative ( Prof Richard Sullivan, Dr Ishu Kataria and Dr Arunah Chandran )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

More from ecancer